RxDoctor Payments Data

Robert Topkis, DO

Family Medicine · Warminster, PANPI 1649367681

Payments from drug & device makers

$28,335in general payments, 2019–2025

Across 1,422 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4K
  • AbbVie$3K
  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Johnson & Johnson$2K
  • Lilly USA, LLC$2K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$1,2504%
  • Food & beverage$26,69194%
  • Education$3941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer223$4,015
AbbVie(2 entities)227$3,318
AstraZeneca118$2,684
Novo Nordisk94$1,807
Johnson & Johnson36$1,585
Lilly USA, LLC80$1,583
GSK78$1,420
Bayer43$1,036
Merck54$980
Amgen(2 entities)42$873
Sanofi-aventis U.S. LLC31$795
Abbott26$778
Boehringer Ingelheim56$750
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)20$597
Astellas Pharma US Inc18$591
Axsome Therapeutics, Inc.22$574
Otsuka America Pharmaceutical, Inc.16$463
Amarin Pharma, Inc.33$447
Teva Pharmaceuticals USA, Inc.16$393
Takeda Pharmaceuticals U.S.A., Inc.26$392
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$368
Kowa Pharmaceuticals America, Inc.20$364
Idorsia Pharmaceuticals US Inc9$256
Biohaven Pharmaceuticals, Inc.9$232
Exact Sciences11$204
Biohaven Pharmaceutical Holding Company Ltd.7$135
Merz North America, Inc.2$126
Dermavant Sciences, Inc.1$120
Ironshore Pharmaceuticals Inc.6$117
Intra-sana Laboratories6$106
Zyla Life Sciences, Inc.6$100
Novartis6$90
Inspire Medical Systems, Inc.4$90
Lundbeck LLC5$89
Almatica Pharma LLC4$86
Verona Pharma, Inc.4$77
Impel Pharmaceuticals Inc.3$63
Scilex Pharmaceuticals Inc.3$60
Eisai Inc.3$53
E.r. Squibb & Sons, L.L.C.3$50
Adlon Therapeutics L.p.3$49
Biogen2$37
Actelion Pharmaceuticals US, Inc.2$36
Forte Bio-pharma LLC1$35
Xeris Pharmaceuticals, Inc.2$35
Assertio Therapeutics, Inc.2$35
Supernus Pharmaceuticals, Inc.1$25
Sanofi Pasteur Inc.1$24
Corcept Therapeutics1$24
Genentech USA, Inc.1$21
Antares Pharma, Inc.1$19
Tolmar, Inc.1$19
Daiichi Sankyo Inc.1$17
Intuity Medical Inc1$15
Phathom Pharmaceuticals, Inc.1$14
Althera Pharmaceuticals LLC1$13
Electromed, Inc.1$13
Medtronic1$13
Vertos Medical, Inc.1$12
Clarus Therapeutics Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,335 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$233,423
Medicare patients
531
Services billed
4,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide174$177,194
JardianceEmpagliflozin119$116,967
EliquisApixaban92$87,747
FarxigaDapagliflozin Propanediol95$77,792
OzempicSemaglutide77$75,925
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$60,103
TrulicityDulaglutide25$26,799
Tresiba Flextouch U-100Insulin Degludec35$21,646
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$17,951
RybelsusSemaglutide14$15,577
XareltoRivaroxaban14$13,799
VerquvoVericiguat13$12,862
VascepaIcosapent Ethyl21$12,823
LinzessLinaclotide16$11,637
JanuviaSitagliptin Phosphate13$11,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,583$203,994199 claims
Boehringer IngelheimJardiance$750$116,967119 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,420$92,738138 claims
Novo NordiskOzempic, Rybelsus$1,807$91,50291 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,684$88,583121 claims
PfizerEliquis$4,015$87,74792 claims
MerckVerquvo, Januvia$980$24,34226 claims
AbbVieLinzess, Synthroid$3,318$15,22172 claims
Johnson & JohnsonXarelto$1,585$13,79914 claims
Astellas Pharma US IncMyrbetriq$591$10,46118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Warminster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →